KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Bristol Myers Squibb (BMY) over the last 17 years, with Q3 2025 value amounting to $96.9 billion.

  • Bristol Myers Squibb's Liabilities and Shareholders Equity rose 343.65% to $96.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $376.6 billion, marking a year-over-year decrease of 154.53%. This contributed to the annual value of $92.6 billion for FY2024, which is 268.6% down from last year.
  • As of Q3 2025, Bristol Myers Squibb's Liabilities and Shareholders Equity stood at $96.9 billion, which was up 343.65% from $94.7 billion recorded in Q2 2025.
  • Bristol Myers Squibb's Liabilities and Shareholders Equity's 5-year high stood at $112.4 billion during Q1 2021, with a 5-year trough of $91.3 billion in Q3 2023.
  • In the last 5 years, Bristol Myers Squibb's Liabilities and Shareholders Equity had a median value of $96.8 billion in 2022 and averaged $98.9 billion.
  • As far as peak fluctuations go, Bristol Myers Squibb's Liabilities and Shareholders Equity crashed by 1349.12% in 2021, and later skyrocketed by 503.81% in 2024.
  • Bristol Myers Squibb's Liabilities and Shareholders Equity (Quarter) stood at $109.3 billion in 2021, then fell by 11.43% to $96.8 billion in 2022, then fell by 1.72% to $95.2 billion in 2023, then fell by 2.69% to $92.6 billion in 2024, then grew by 4.63% to $96.9 billion in 2025.
  • Its last three reported values are $96.9 billion in Q3 2025, $94.7 billion for Q2 2025, and $92.4 billion during Q1 2025.